ASH 2017 Annual Meeting Highlights in Hodgkin Lymphoma


Early Interim PET in Patients with Advanced-Stage HL Treated within the Phase 3 GHSG HD18 Study
Peter Borchmann, MD

Begin


Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Robert W. Chen, MD

Begin


Phase 2 Checkmate 205 Study Looking at Nivolumab for Newly Diagnosed Advanced-Stage cHL and Outcomes in Patients with Relapsed/Refractory cHL
Jonathon B. Cohen, MD, MS

Begin


Positive Phase 3 Data from ECHELON 1 Clinical Trial Comparing A+AVD as Frontline Therapy in Previously Untreated Advanced HL
Joseph M. Connors, MD, FRCPC

Begin


Studies That Will Impact or Shape Treatment of HL in 2018
Matthew Matasar, MD

Begin